Source link : https://www.newshealth.biz/health-news/immunotherapy-combo-active-in-advanced-pd-l1-negative-hnscc/
A chemotherapy-free regimen combining the investigational therapy eftilagimod alpha with pembrolizumab (Keytruda) showed promising efficacy in a small cohort of patients with recurrent or metastatic PD-L1–negative head and neck squamous cell carcinoma (HNSCC). The combination led to an objective response rate (ORR) of 35.5% as first-line treatment among 31 HNSCC patients with a PD-L1 combined […]
Author : News Health
Publish date : 2024-07-12 17:03:51
Copyright for syndicated content belongs to the linked Source.
Categories